{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:11:07Z","timestamp":1792440667875,"version":"4.5.0"},"reference-count":9,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Oral Pathology Medicine"],"published-print":{"date-parts":[[2021,4]]},"abstract":"Abstract<\/jats:title>\n \n Introduction<\/jats:title>\n Adverse events associated with vaccine administration can manifest in the oral cavity and orofacial region. Hence, the aim of this study was to compare the orofacial adverse effects of two recently authorised COVID\u201019 vaccines, namely BNT162b2 and mRNA\u20101273.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Publicly available data on BNT162b2 and mRNA\u20101273 vaccines were accessed from the relevant regulatory authorities in the United States, Canada, European Union and United Kingdom. Both patient\/recipient information and healthcare professional fact sheets for each of these drugs were manually searched to find their orofacial adverse effects.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Adverse events affecting the orofacial region were reported for both vaccines. These were rare and included acute peripheral facial paralysis (Bell's palsy), facial swelling, and swelling of the lips, face or tongue associated with anaphylaxis. There was heterogeneity in the acknowledgement of vaccine\u2010related adverse events in North America compared with Europe.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Globally, there are inconsistencies in the description of adverse effects presenting in the orofacial region of the COVID\u201019 vaccines BNT162b2 and mRNA\u20101273. We believe that awareness of these orofacial manifestations will improve recognition, management and reporting of vaccine\u2010related adverse effects.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jop.13165","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T16:02:48Z","timestamp":1612368168000},"page":"424-427","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Reported orofacial adverse effects of COVID\u201019 vaccines: The knowns and the unknowns"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1429-1323","authenticated-orcid":false,"given":"Nicola","family":"Cirillo","sequence":"first","affiliation":[{"name":"Melbourne Dental School The University of Melbourne Melbourne Vic. Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-019-03635-9"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2005630"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198114"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"e_1_2_8_6_1","article-title":"Efficacy and safety of the mRNA\u20101273 SARS\u2010CoV\u20102 vaccine","author":"Baden LR","year":"2020","journal-title":"N Engl J Med"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m4750"},{"key":"e_1_2_8_8_1","unstructured":"US Food and Drug Administration.Pfizer\u2010BioNTech COVID\u201019 Vaccine Emergency Use Authorization Review Memorandum.2020;https:\/\/www.fda.gov\/media\/144416. Accessed 15th January 2021"},{"key":"e_1_2_8_9_1","unstructured":"Medicines and Healthcare products Regulatory Agency.Information for Healthcare Professionals on COVID\u201019 Vaccine Moderna.https:\/\/www.gov.uk\/government\/publications\/regulatory-approval-of-covid-19-vaccine-moderna\/information-for-healthcare-professionals-on-covid-19-vaccine-moderna[Accessed 15th January 2021]"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/odi.13199"}],"container-title":["Journal of Oral Pathology & Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jop.13165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jop.13165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jop.13165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T15:56:54Z","timestamp":1693583814000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jop.13165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["10.1111\/jop.13165"],"URL":"https:\/\/doi.org\/10.1111\/jop.13165","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/JOP.13165\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0904-2512","1600-0714"],"issn-type":[{"value":"0904-2512","type":"print"},{"value":"1600-0714","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"2021-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}